Trial Profile
The clinical study to evaluate the efficacy, safety, and pharmacokinetics of MD-0901 in pediatric patients with ulcerative colitis in remission.
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Mochida Pharmaceutical
- 14 Dec 2017 New trial record